Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database

missing outcome data and the relatively short exposure to secukinumab.The majority of patients discontinued in the first trimester, whereas secukinumab would be expected to be transferred across the placenta in the third trimester.There are no human data on the effects of secukinumab on the immune system of neonates born after in utero exposure.Although there may be a bias towards reporting of detrimental events, there was no evidence for increased rates of adverse pregnancy outcomes with secukinumab in this review of the safety database.However, given the limited exposure reported to date, the continuous use of secukinumab throughout pregnancy requires further research.